🇺🇸 FDA
Patent

US 10202366

Methods of promoting wound healing using CRM1 inhibitors

granted A61KA61K31/41A61K31/4196

Quick answer

US patent 10202366 (Methods of promoting wound healing using CRM1 inhibitors) held by Karyopharm Therapeutics Inc. expires Mon Feb 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Karyopharm Therapeutics Inc.
Grant date
Tue Feb 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61K, A61K31/41, A61K31/4196, A61P, A61P17/02